Apalutamide 60mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 60mg

Reference Brands: ERLEADA (USA/EU)

Category: Oncology Cancer Care

Apalutamide is a next-generation androgen receptor inhibitor used for the treatment of prostate cancer, including non-metastatic castration-resistant and metastatic castration-sensitive forms. It works by blocking the effects of androgens, hormones that promote the growth of prostate cancer cells. Administered orally, Apalutamide is often used in combination with androgen deprivation therapy (ADT). Erleada has become an important option in prolonging survival and delaying disease progression in prostate cancer patients.

Product Description:

Apalutamide is a second-generation androgen receptor inhibitor. Prostate cancer depends on androgen signalling, and first-generation antiandrogens block the receptor only partially and can eventually act as agonists. Apalutamide binds the receptor with much higher affinity, prevents it moving into the nucleus, stops it binding DNA and blocks its recruitment of coactivators — three points of interruption rather than one.

It is used with androgen deprivation therapy for non-metastatic castration-resistant prostate cancer and for metastatic hormone-sensitive disease. In the first of those it markedly delayed the appearance of metastases, which was the endpoint that established the modern treatment of a disease state previously managed by watching a rising PSA. Skin rash is more frequent than with other agents in the class and can be severe. Falls and fractures increase, hypothyroidism occurs, and seizure risk means caution where the threshold is lowered. It induces several cytochrome enzymes, so interaction review is essential.

Sourcing notes. Originator product, on patent, no generic. It competes directly with enzalutamide and darolutamide, and the choice between them turns on toxicity profile and price rather than efficacy. Treatment continues for years, so volume per patient is high.